Publications

View and download slide summaries of the latest original articles focusing on therapies in immune-mediated inflammatory diseases including rheumatology, dermatology, and gastroenterology. All materials produced by the team are subsequently reviewed and approved by individual Steering Committee members.

June 2024

Upadacitinib in active non-radiographic axial spondyloarthritis: 1-year data from a double-blind, randomized, placebo-controlled, Phase 3 trial

ACR Open Rheumatol 2024 doi: 10.1002/acr2.11669 Epub ahead of print

Kim TH,

Li Y,

Wung P,

The 1-year results of the SELECT-AXIS 2 study showed significant improvements in ASAS40 achievement in patients with nr-axSpA that were treated with upadacitinib 15mg QD versus placebo. Improvements in ASDAS endpoints, back pain, BASFI, and hsCRP from baseline were also observed.

Keywords:

Long-term clinical outcomes of certolizumab pegol treatment in non-radiographic axial spondyloarthritis stratified by baseline MRI and CRP status

RMD Open 2024;10:e003884 doi: 10.1136/rmdopen-2023-003884 https://pubmed.ncbi.nlm.nih.gov/38724259/

Bauer L,

Kumke T,

Kim M,

The safety follow-up extension of the C-axSpAnd trial showed that long-term clinical outcomes from certolizumab pegol treatment achieved after 1 year were generally sustained at 3 years across MRI+/CRP+, MRI−/CRP+ and MRI+/CRP− subgroups.

Keywords:

April 2024

Comparative effectiveness of tofacitinib and adalimumab in axial spondyloarthritis: A real-world clinical context multicenter study

J Clin Rheumatol 2024 doi 10.1097/RHU.0000000000002069

Goswami RP,

Sinha D,

Chatterjee M,

Bhadu D,

Das S

This study by Goswami, et al. found that tofacitinib showed comparable effectiveness with adalimumab in axSpA patients at the sixth month.